Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Debt Repayments (2022 - 2024)

Eton Pharmaceuticals (ETON) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $385000.0 as the latest value for Q3 2024.

  • Quarterly Long-Term Debt Repayments changed 0.0% to $385000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $385000.0 through Jun 2025, down 75.0% year-over-year, with the annual reading at $1.2 million for FY2024, 0.0% changed from the prior year.
  • Long-Term Debt Repayments hit $385000.0 in Q3 2024 for Eton Pharmaceuticals, roughly flat from $385000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $385000.0 in Q1 2022 to a low of $385000.0 in Q1 2022.
  • Historically, Long-Term Debt Repayments has averaged $385000.0 across 3 years, with a median of $385000.0 in 2022.
  • Biggest YoY gain for Long-Term Debt Repayments was 0.0% in 2024; the steepest drop was 0.0% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $385000.0 in 2022, then changed by 0.0% to $385000.0 in 2023, then changed by 0.0% to $385000.0 in 2024.
  • Business Quant data shows Long-Term Debt Repayments for ETON at $385000.0 in Q3 2024, $385000.0 in Q2 2024, and $385000.0 in Q1 2024.